Pretorius, L., Pol, K., Perenboom, C., Appleton, K. M., James, J. and Mars, M., 2025. Effects of L-Arabinose on Glycemic Responses After the Consumption of Sucrose-Rich Foods in Individuals with Impaired Fasting Glucose: A Randomized Controlled Cross-Over Trial. Journal of Nutrition, 155 (9), 3030-3039.
Full text available as:
Preview |
PDF (OPEN ACCESS ARTICLE)
1-s2.0-S0022316625004171-main.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
|
Copyright to original material in this document is with the original owner(s). Access to this content through BURO is granted on condition that you use it only for research, scholarly or other non-commercial purposes. If you wish to use it for any other purposes, you must contact BU via BURO@bournemouth.ac.uk. Any third party copyright material in this document remains the property of its respective owner(s). BU grants no licence for further use of that third party material. |
DOI: 10.1016/j.tjnut.2025.06.028
Abstract
Background: Impaired fasting glucose (IFG) is considered a preclinical stage of type 2 diabetes. L-arabinose is a sucrase inhibitor that interferes with sucrose breakdown and has been shown to lower glycemic and insulinemic responses in healthy individuals. However, its effects in individuals with IFG are unknown. Objectives: This study aims to assess effects of L-arabinose on glycemic responses after the consumption of sucrose-rich foods in individuals with IFG. Methods: Eighteen adults [4 females, 14 males; age 73 ± 4 y; body mass index 27.5 ± 2.4 kg/m<sup>2</sup>] with IFG participated in a double-blind, randomized, cross-over trial. Participants received 10% w/w L-arabinose (treatment) in a 550 mL sucrose drink or a sucrose-only drink (control). Blood glucose and insulin were measured before and ≤180 min post consumption. After this, participants consumed a 2-day controlled diet with sucrose-rich (9–10 en%) meals and snacks, preceded by a 15% w/w L-arabinose supplement or no L-arabinose (control). Continuous glucose monitoring (CGM) assessed glycemic variability throughout the trial. Results: A single treatment of 10% w/w L-arabinose significantly reduced glucose peaks (–14%) and insulin peaks (–30%), with delays of 10 and 32 min, respectively. CGM also revealed significant reductions in variability compared with control value: standard deviation (–25%), coefficient of variation (–24%), and mean amplitude of glycemic excursions (–26%). However, no effects on glycemic variability were observed during the controlled diet. Conclusions: A single treatment of L-arabinose to a sucrose-rich drink reduced insulin and glucose responses in individuals with IFG, but this effect did not extend to a sucrose-rich diet containing complex meals and snacks. Trial registration number: https://onderzoekmetmensen.nl/nl/trial/27001.
| Item Type: | Article |
|---|---|
| ISSN: | 0022-3166 |
| Uncontrolled Keywords: | L-arabinose; continuous glucose monitoring; glucagon; glucose; impaired fasting glucose; insulin |
| Group: | Faculty of Science & Technology |
| ID Code: | 41532 |
| Deposited By: | Symplectic RT2 |
| Deposited On: | 20 Nov 2025 12:41 |
| Last Modified: | 20 Nov 2025 12:41 |
Downloads
Downloads per month over past year
| Repository Staff Only - |
Tools
Tools